The Edit Review: $249 NAD+ and a Prescriber You Can Check

The Edit (theedithealth.com) sells injectable NAD+ at $249 a month, which is at the expensive end of everything on our NAD+ price index. We are filing it with more confidence than most numbers we file, and the reason has nothing to do with the number.

Why we trust the figure

The Edit publishes its whole menu twice — once on a product index, once on six individual product pages — and the two surfaces agree exactly. Its weight-loss line carries prepay tiers, and every one of them divides correctly into the per-month figure printed next to it. Its prepay rungs are labeled as billed once at the start of a plan rather than dressed up as monthly rates. Nothing on the price surface contradicts anything else on it.¹

That sounds like a low bar. In this category it is not. The failure mode we correct most often is a provider whose cheapest published figure turns out to be an annual membership divided by twelve, a first-month promotion, or a prepay commitment shown with a slash-mo after it. An operator whose checkable arithmetic all checks out has earned a bit of credit on the parts you cannot check — and there is one part here you cannot check.

We could not reach a checkout price. The intake requires walking a questionnaire, and no price table is reachable before that point. So $249 is the published price, corroborated on two independent surfaces of the company's own site, and that is exactly the claim we are making — not that we watched a card get charged.

The rest of the shelf

Six prescription protocols, all injectable except the GHK-Cu cream. There is no oral NAD+, no nasal spray, no research-chemical line, and the site states plainly that it does not sell research-use-only compounds. For a category where the catalog is often the tell, that is a short and unusually disciplined list.

What the $249 actually buys

An injection, once again, of a compound with no human trial behind the route.

There is no published pharmacokinetic study of subcutaneous NAD+ in people. The only human study of administered NAD+ we can point to is a small pilot in which participants received a six-hour intravenous infusion, and it measured what appeared in plasma and urine rather than whether anyone felt or functioned differently.² Injection is not IV, and even the IV literature ends there. We lay the whole thing out in what the injection evidence shows.

What does have controlled human data is the oral precursor route. Nicotinamide riboside is orally bioavailable and raises blood NAD+ in humans,³ reliably and with good tolerability over months of dosing,⁴ and it does the same in aged human skeletal muscle.⁵ The catch is the part after the biomarker: a systematic review of precursor trials found the metabolic benefits limited and inconsistent even where NAD+ rose,⁶ a randomized NMN trial raised NAD+ without delivering a dramatic functional payoff,⁷ and the clearest positive human signal in the literature is narrow.⁸

So the comparison a buyer should actually be making is not "$249 versus $209 somewhere else". It is "$249 a month for a route nobody has measured, versus a fraction of that for a route with trials behind the biomarker and a thin record on the outcomes". Is NAD+ therapy worth it works through that properly.

The disclosure record — the best in this batch

Two things here are close to unique among the six providers we read in August 2026.

The pharmacy is named. The Pharmacy Hub, described as sitting inside the company's pharmacy network. Because compounded NAD+ is compounded, sterility and dosing accuracy live entirely with the pharmacy, and most operators in this category will describe a category ("a 503A pharmacy") or a network without ever naming a facility you could look up.

A prescriber is named and the NPI verifies. The medical group is Arora Health & Aesthetics, LLC, with medical director Dr. Sean Arora, NPI 1841729449 — which we checked against the national provider registry and found active, family medicine, Seattle. A published NPI that resolves is a fact a reader can confirm without trusting us, which is the only kind of credential worth printing.

The corporate entity is The Edit Health LLC, a Texas company operating as a management services organization, with a published Austin address. All fifty states, per the terms and the help center, with address-level eligibility confirmed at consultation. Getting started is free — no charge and no card on file to begin, and a full refund if you are not approved. Compounded prescriptions are final sale once dispensed, and membership cancels at the end of the current period with no pro-rating. The site also ships a complete Spanish mirror of every page, which is rare enough to be worth noting even on an English-language site.

The knock

Three things.

$249 is a lot. It is near the top of the prescription NAD+ range we track, for a compounded product that is clinically indistinguishable from the cheaper ones. Nothing about the transparency changes what is in the vial.

The clean arithmetic is not a clinical claim. A company can publish an impeccable price table for a product with no evidence behind it, and that is precisely what is happening. Careful pricing tells you about the operator; it tells you nothing about the molecule or the route.

It shares a medical group with another provider in this batch. The Edit and Trellis Vitality both run on Arora Health & Aesthetics and the same medical director. They use different pharmacies and charge different prices, so they are separable products — but if you are shortlisting both as independent second opinions, they are not. Whichever you choose, the same medical group is behind the prescription.

The regulatory screen

The brand, the legal entity, the medical group and the named pharmacy all returned zero company-column matches in the FDA's live warning-letter index when we screened them in August 2026.⁹ The screen carried a positive control — an unrelated telehealth seller with a letter on the record — which returned correctly each time, so the zero is a result rather than a query that failed silently.

Where it lands

The Edit is the provider in this batch we would trust most and recommend least on price. If you want a compounded NAD+ injection and you care about being able to name the pharmacy filling it and look up the doctor signing for it, there is no better-documented option among the six. If your question is how to raise NAD+ for the least money with the most evidence, the answer is not on this menu, and it is not on anyone else's either — it is an oral precursor, covered in is nicotinamide riboside worth it and NMN vs NR.

For the price surfaces we compare it against, see Auren Rx's seven published NAD+ rungs and the flagship program that never published a ladder. Providers we do have a commercial relationship with are ranked and disclosed on our NAD+ rankings hub.